Schizophrenia care and the Dutch community pharmacy: The unmet needs

International Journal of Pharmacy Practice

Volumn 11, Issue 2, 2003, Pages 97-104

  Rijcken, C A W ^c   Van der Veur, H ^c   Knegtering, H ^a   De Jong van den Berg, Lolkje T W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Antonius Deusinglaan 1   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PHARMACY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELATIVE; SCHIZOPHRENIA; SIDE EFFECT; SUPPORT GROUP;

EID: 0038113243     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357021288     Document Type: Article

References (32)

1. Jong de A, Brink van den W, Ormel J, Wiersma D. Handbook of psychiatric epidemiology (Handboek psychiatrische epidemiologie). 1st ed. Maarssen: Elsevier/De Tijdstroom; 1999.
2. Power P, Elkins K, Adlard S, Curry C, McGorry P, Harrigan S. Analysis of the initial treatment phase of first-episode psychosis. Br J Psychiatry 1998;172 Suppl 33:71-6.
3. Robinson D, Woerner M, Alvir JM, Bilder R, Goldman R, Geisler S et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.
4. Kasper S, Hale A, Azorin JM, Moller HJ. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2000;249 Suppl 2:S2-S14.
5. Remmington G, Kapur S. Atypical antipsychotics: are some as atypical as others? Psychopharmacology 2000;148:3-15.
6. Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002;53:145-59.
7. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206.
8. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999;60:5-9.
9. Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry 1998;172 (S33):66-70.
10. Montero L, Asencio AP, Ruiz I, Hernandez I. Family interventions in schizophrenia: an analysis of non-adherence. Acta Psychiatr Scand 1999;100:136-41.
11. Agarwal MR, Sharma VK, Kumar KV, Lowe D. Noncompliance with treatment in patient suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44:92-106.
12. Tamminga CA. Gender and schizophrenia. J Clin Psychiatry 1997;58 Suppl 15:33-7.
13. Kane JM. Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry 1983;44:3-6.
14. Naber D, Moritz S, Rajonk F, Holzbach R, Mass R, Andresen B et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
15. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001;11:S391-6.
16. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Compr Psychiatry 2000;41:446-9.
17. Azrin NH, Teichner G. Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients. Behav Res Ther 1998;36:849-61.
18. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653-64.
19. Grootheest van AC, Puijenbroek van EP, De Jong-Van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11:205-10.
20. Donoghue JM. Problems with psychotropic medicines in the community. Pharm J 1993;251:350-2.
21. Donoghue JM. Community pharmacists: meeting mental health needs in primary care. Prim Care Psychiatry 1995;1:39-44.
22. Ewan MA, Greene RJ. Provision of a community pharmacist-run medication advice service at mental health resource centres. Psych Bull 2000;24:294-8.
23. Ewan MA, Greene RJ. Evaluation of mental health care interventions made by three community pharmacists - a pilot study. Int J Pharm Pract 2001;9:234.
24. Branford D. Pharmaceutical services to the mentally ill. J Roy Soc Health 1991;8:150-1.
25. Cohen LJ. The emerging role of psychiatric pharmacists. Am J Manage Care 1999;5:S620-S629.
26. Watson PJ. Community pharmacists and mental health: and evaluation of two pharmaceutical care programmes. Pharm J 1997;258:419-22.
27. Kumar R. Selecting a method for data collection. In Kumar R, editor. Research methodology. London: SAGE Publications; 1999. p103-25.
28. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Comm Pharm 1990;41:1203-11.
29. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35:S67-S73.
30. Cohen LJ. The role of neuropsychiatric pharmacists. J Clin Psychiatry 1999;60:54-7.
31. Maslen CL, Rees L, Redfern PH. Role of the community pharmacist in the care of patients with chronic schizophrenia in the community. Int J Pharm Pract 1996;4:187-95.
32. NIPO i.s.m. Ypsilon [Dutch Market Research Institute in collaboration with Ypsilon]. Het gebruik van antipsychotica: een onderzoek onder schizofreniepatinten en (hun) familieleden. [The use of antipsychotics: a study among patients with schizophrenia and their family members]: http://www.nipo.nl, consulted May 14, 2002.